Payal Shah, MD
Medical Oncology · Philadelphia, PANPI 1730323676
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,324 of the $18,713 with a category attached, or 92.6%. 5 manufacturers reported payments, led by Gilead at 59.4% of the total. Reporting peaked in 2023 at $8,424 and has fallen 63.9% since, to $3,040 in 2025.
Across 20 payments — averaging $935.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$11K
- AstraZeneca$5K
- Daiichi Sankyo Inc.$3K
- Astrazeneca UK Limited$135
- Genentech USA, Inc.$123
Across 26 payments — averaging $138,759 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.3M
- Pfizer$1.3M
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Consulting fees$17,32493%
- Grants$2501%
- Travel & lodging$7104%
- Food & beverage$4292%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 11 | $11,121 |
| AstraZeneca | 5 | $4,765 |
| Daiichi Sankyo Inc. | 2 | $2,569 |
| Astrazeneca UK Limited | 1 | $135 |
| Genentech USA, Inc. | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,713 in reported general payments places this provider in the 70th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 14 | $207,259 |
| Anastrozole | 38 | $1,106 |
| Letrozole | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.